Skip to main content

Advertisement

Table 2 Characteristics of testosterone replacement therapy (TRT) trials reporting both serum testosterone (T) and dihydrotestosterone (DHT) concentrations before and after treatment

From: Cardiovascular risks and elevation of serum DHT vary by route of testosterone administration: a systematic review and meta-analysis

Author/Year Study type Mode Dose Duration Age Subjects in TRT group Serum T at entry Health status
Amory 2004 [32] RCT i.m. 100 mg TE/week 36 months 71 ± 4 (SD) 24 302 ± 48 (SD) ng/dL hypogonadal
Arver 1997 [65] open-label i.m. 266 mg TE/26 days 3 weeks 58 ± 10 (SD) 27 121 ± 100 (SD) ng/dL hypogonadal
Bhasin 2012 [66] RCT i.m. 125±mg TE/week 5 months 40 ± 7 (SD) 12 519 ng/dL (mean) eugonadal
Borst 2014 [34] RCT i.m. 125 mg TE/week 12 months 69.2 ± 8.0 (SD) 31 264 ± 92 (SD) ng/dL hypogonadal
Lakshman 2010 [67] RCT i.m. 125 mg TE/week 5 months 65.6 ± 4.3 (SD) 11 581 ± 168 (SD) ng/dL eugonadal
Raynaud 2008 [68] open-label i.m. 250 mg TE/3 weeks 12 months 41.8 ± 12.4 (SD) 32 43 ng/dL (mean) hypogonadal
Shubert 2003 [69] open-label i.m. 250 mg TE/3 weeks 12 months 31.9 ± 2.5 (SD) 14 63.6 ng/dL ±14 (SD) hypogonadal
Wang 2010 [70] open-label i.m. 750 mg TU/4 to 10 weeks 21 months >18 117 320 ng/dL ±111 (SD) low normal T
Brockenbrough 2006 [48] RCT gel 10 mg T/day 6 months 58.9 ± 14.9 (SD) 19 218 ± 64 (SD) ng/dL hypogonadal, renal disease
Cherrier 2003 [71] RCT gel 50-100 mg T/day 6 months 34 to 70 12 320 ± 90 (SD) ng/dL low normal T
Chiang 2007 [72] RCT gel 50 mg T/day 3 months 20 to 75 17 213 ± 158 (SD) ng/dL hypogonadal
Dean 2004 [73] open-label gel 50 mg T/day 9 months 58.5 (mean) 257 247 ng/dL (mean) hypogonadal
Di Luigi 2012 [74] open-label gel 50 mg T/day 1.25 month 31.3 ± 7.5 (SD) 10 72 ng/dL (mean) hypogonadal
Juang 2014 [75] RCT gel 100 mg T/day 3.5 months 24 to 51 14 302 ± 37 (SD) ng/dL hypogonadal, osteoporosis
Kenny 2010 [53] RCT gel 50 mg T/day 12 months 79.9 ± 7.3 (SD) 69 380 ± 179 (SD) ng/dL eugonadal, osteoporosis
Marin 1993 [54] RCT gel 125 mg T/day 9 months 56.7 ± 2.2 (SD) 10 455 ± 23 (SD) ng/dL eugonadal, obese
Mazer 2005 [76] RCT gel 59 mg/day 2 weeks 52.4 ± 12.2 (SD) 28 226 ± 110 (SD) ng/dL hypogonadal
Page 2011 [77] RCT gel 75 mg T/day 6 months >50 27 204 ng/dL (mean) hypogonadal, BPH
Swerdloff 2000 [78] open-label gel 100 mg T/day 3 months 51.3 (mean) 76 280 ng/dL (mean) hypogonadal
Wang 2000 [79] no placebo group gel 100 mg T/day 2 weeks 26 to 59 10 179 ± 41 (SD) ng/dL hypogonadal
Wang 2011 [80] open-label gel 60 mg T/day 4 months 51.5 ± 12.7 (SD) 135 215 ± 84 (SD) ng/dL hypogonadal
Ahmed 1988 [81] no placebo group patch 15 mg T/day 6 to 8 weeks 34 to 54 5 45 ± 12 (SD) ng/dL hypogonadal
Bals-Pratch 1988 [82] not stated patch 10 to 15 mg T/day 14 months 31 to 37 7 189 ng/dL (mean) hypogonadal
Behre 1999 [83] open-label patch 2.4 to 3.6 mg T/day 7 years 35.9 ± 9.8 (SD) 11 147 ± 37 (SD) ng/dL hypogonadal
Cunningham 1989 [84] placebo-controlled patch 15 mg T/day 8 weeks 33 to 66 12 43 ± 11 (SD) ng/dL hypogonadal
Mazer 2005 [76] open-label patch 5 mg T/day 2 weeks 28 to 71 28 215 ± 110 (SD) ng/dL hypogonadal
Meikle 1992 [85] not stated patch 12.6 mg T/day single dose 24 to 66 6 161 ± 27 (SD) ng/dL hypogonadal
Raynaud 2008 [68] open-label patch 2.5 mg T/day 12 months 40.7 ± 10.5 (SD) 131 43 ng/dL (mean) hypogonadal
Franchimont 1978 [86]   oral 120 to 240 mg TU/day 9 weeks 16 to 51 10 120 ng/dL (mean) hypogonadal
Roth 2011 [87] open-label oral 400 mg TU/day 1 day 18 to52 11 405 ± 14 (SD) ng/dL eugonadal
Schubert 2003 [69] open-label oral 160 mg TU/day 12 months 34.5 ± 3.9 (SD) 13 63.6 ng/dL ±14 (SD) hypogonadal
Van Coevorden 1986 [88] RCT oral 240 mg TU/day 12 weeks 40 ± 11 (SD) 19 161 ± 86 (SD) ng/dL hypogonadal, renal insufficiency
  1. BPH, benign prostate hyperplasia; RCT, randomized clinical trial; SD, standard deviation; TE, testosterone enanthate; TU, testosterone undecanoate.